BiotechTube

Esomeprazole Sodium

ApprovedCompleted
5 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Gastric Ulcer

Conditions

Gastric Ulcer

Trial Timeline

Oct 1, 2006 → Nov 1, 2006

NCT ID
NCT00428701

About Esomeprazole Sodium

Esomeprazole Sodium is a approved stage product being developed by AstraZeneca for Gastric Ulcer. The current trial status is completed. This product is registered under clinical trial identifier NCT00428701. Target conditions include Gastric Ulcer.

What happened to similar drugs?

4 of 20 similar drugs in Gastric Ulcer were approved

Approved (4) Terminated (3) Active (14)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅ApatinibJiangsu Hengrui MedicineApproved
✅trastuzumab [Herceptin]RocheApproved
✅Methylnaltrexone only + Codeine only + Methylnaltrexone + codeine + Placebo + placeboPfizerApproved
🔄Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
❌Irinotecan + NimotuzumabDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00428701ApprovedCompleted

Competing Products

20 competing products in Gastric Ulcer

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
32
InfigratinibLianBioPhase 2
17
InfigratinibLianBioPhase 2
21
Ramucirumab + MEDI4736Eli LillyPhase 1
29
RamucirumabEli LillyPhase 2
35
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
31
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
40
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
42
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
44
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
42
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
33
DS-8201aDaiichi SankyoPhase 1
29
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
32
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
47
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
39